Effects of Resistance Training on Substrate Metabolism During the Menstrual Cycle

September 27, 2021 updated by: Southern Illinois University Edwardsville

Acute Effects of Resistance Training on Substrate Metabolism During Different Phases of Menstrual Cycle

This research project's objective is to investigate substrate metabolism behavior in response to the RT during different phases of the menstrual cycle.

Study Overview

Detailed Description

Based on the literature the investigators hypothesize an increase in fat oxidation in early follicular phase(EFP) and late follicular phase (LFP) when compared to early luteal phase (ELP) and late luteal phase (LLP). Given the lack of research in exercise and menstrual cycle - especially in resistance training - results are uncertain unless the investigators base their hypotheses only on the general physiological effects of sex hormones (without exercise). In this case, the investigators expect to see a reduced carbohydrate utilization and an increased utilization of fats in EFP and LFP. In addition, the intervention is focused on muscular endurance and, therefore, it is expected to see a higher reliance on aerobic pathways. It is expected that the effects of the intervention will be added to the effects of estrogens, with increasing fat oxidation when estrogen levels are higher. Lastly, a comparison of fat oxidation levels obtained on each sub-phase would reveal if there are differences in the magnitude of the effect of distinct concentrations of estrogen and progesterone.

Study Type

Interventional

Enrollment (Actual)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Illinois
      • Edwardsville, Illinois, United States, 62026
        • Southern Illinois University Edwardsville

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Females with BMI-18.5-34.99 and between 18-45 years, with normal menstrual cycle defined as 28-30 days cycles +-3 days.
  • Including higher BMI participants might alter the results as increased body fat has been linked to changes in different hormonal levels (not only sex hormones) and that might influence substrate utilization.
  • Sedentary .or physically active for 2 days a week or less.

Exclusion Criteria:

  • • Musculoskeletal injuries,

    • cardio-respiratory conditions,
    • metabolic conditions,
    • irregular menstrual cycle,
    • menstrual dysfunction or unusual sex hormone levels,
    • on contraceptives,
    • on medication that alter hormonal or cardio-respiratory responses,
    • pre-menopausal symptoms,
    • on moderate to high-intensity exercise regime more than 2d/week.
    • All these exclusion criteria are chosen because any one of the listed criteria above can alter the responses and/or affect the safety of the subject during their participation in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Early Follicular Phase (EFP)
This group is comprised of participants at the Early Follicular Phase (EFP) of the menstrual cycle.
This group will perform the Resistance training intervention on day 4 of the menstrual cycle, which corresponds to the mid of early follicular phase.
Experimental: Late Follicular Phase
This group is comprised of participants at the Late Follicular Phase (LFP) of the menstrual cycle.
This group will perform the Resistance training intervention on day 11 of the menstrual cycle, which corresponds to the mid of late follicular phase.
Experimental: Early Luteal Phase
This group is comprised of participants at the Early Luteal Phase (ELP) of the menstrual cycle.
This group will perform the Resistance training intervention on the day 18 of the menstrual cycle, which corresponds to the mid of early luteal phase
Experimental: Late Luteal Phase
This group is comprised of participants at the Late Luteal Phase(LLP) of the menstrual cycle.
This group will perform the Resistance training intervention on day 21 of the menstrual cycle, which corresponds to the mid of late luteal phase

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in Substrate oxidation
Time Frame: During each exercise session: 1 assessment point on each menstrual cycle phase
changes in substrate oxidation will be measured using cosmed K5 during the intervention phase
During each exercise session: 1 assessment point on each menstrual cycle phase
Changes in Estrogen levels.
Time Frame: At baseline: 1 assessment point on each menstrual cycle phase
Blood would be drawn from the participants for assessment of hormone estrogen
At baseline: 1 assessment point on each menstrual cycle phase
Changes in Progesterone levels.
Time Frame: At baseline: 1 assessment point on each menstrual cycle phase
Blood would be drawn from the participants for assessment of hormone Progesterone.
At baseline: 1 assessment point on each menstrual cycle phase

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Muscular strength
Time Frame: At baseline: 1 assessment point
Muscular strength will be assessed by one-repetition maximum test on leg press and bench press
At baseline: 1 assessment point
Cardiorespiratory Function
Time Frame: At baseline: 1 assessment point
maximal oxygen consumption will measured on a treadmill with a metabolic cart
At baseline: 1 assessment point
Relative Body Fat (%)
Time Frame: At baseline: 1 assessment point
Body composition i.e Fat mass, Lean body mass and Body fat percentage will be measured using dual-energy xray absorptiometry
At baseline: 1 assessment point
Lean Body Mass (kg)
Time Frame: At baseline: 1 assessment point
Body composition i.e Fat mass, Lean body mass and Body fat percentage will be measured using dual-energy xray absorptiometry
At baseline: 1 assessment point
Fat Mass (kg)
Time Frame: At baseline: 1 assessment point
Body composition i.e Fat mass, Lean body mass and Body fat percentage will be measured using dual-energy xray absorptiometry
At baseline: 1 assessment point
Diet
Time Frame: At baseline: 1 assessment point on each menstrual cycle phase
Diet will be measured using ASA-24h recall
At baseline: 1 assessment point on each menstrual cycle phase

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Maria Fernandez del Valle, PhD, Southern Illinois University Edwardsville

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2019

Primary Completion (Actual)

March 16, 2020

Study Completion (Actual)

March 16, 2020

Study Registration Dates

First Submitted

March 21, 2019

First Submitted That Met QC Criteria

July 17, 2019

First Posted (Actual)

July 18, 2019

Study Record Updates

Last Update Posted (Actual)

October 4, 2021

Last Update Submitted That Met QC Criteria

September 27, 2021

Last Verified

July 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • 111A

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Menstrual Cycle

Clinical Trials on EFP

3
Subscribe